The Canadian government has authorized a startup to export psychedelic substances to Australia for therapeutic applications. The health department has commissioned Optimi Health Corp. to transport pills containing psilocybin, a magic mushroom extract, and MDMA.
The rising demand surpasses the local Ontario’s magic mushrooms. Other countries are following Canada’s lead, starting to research and sanction the medicinal use of serotogenic compounds.
Feel assured when you buy psychedelics online in Canada, exploring your inherent potential through trusted sources.
[toc]Main Takeaways:
- Optimi Health, a Vancouver-based startup, has been awarded a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in the treatment of chronic depression.
- The treatment protocol involves three sessions spread over five to eight weeks, with each session lasting about eight hours.
Rising Popularity of Psilocybin Capsules in Canada
Optimi, a Vancouver-based start-up, aims to utilize its certification to broaden the pharmaceutical market for psychedelic drugs and establish an early market presence.
Seven firms have exported psilocybin, MDMA, or both, but only for clinical trials. A spokesperson from Canada’s health department could not confirm if these exports were for regular patient treatment and chose not to reveal the companies due to safety reasons.
This accomplishment places Optimi among a handful of global suppliers, with the current market trend favoring clinical over recreational use.
What Does the Pill Contain?
The company has not disclosed the specific type of mushroom used in the pill, but they do collaborate with various strains like the Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, analyze, and extract its psychedelic mushrooms. This quaint town, with a population nearing 3,000, is situated three hours east of Vancouver.
Australia and Psychedelic Mushrooms: A Crucial Connection
Statistics suggest that mental illness may affect 1 in every 5 Australians between the ages of 16 and 85. Post-traumatic stress disorder (PTSD) could potentially impact 11% of Australians at some point, while anxiety disorders are prevalent in 17% of the population.
There is a plethora of methods available for treating mental conditions, but their effectiveness varies from person to person. For patients who don’t respond to certain treatments, finding a suitable alternative can be daunting, thereby compounding their vulnerability.
Understanding the Process
Australia has been a trailblazer in the medical use of psilocybin, allowing trained psychiatrists to administer this controlled substance for treatment-resistant PTSD and depression.
In an unexpected move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and psychedelic mushrooms for therapeutic usage. The TGA highlighted that these substances are safe when used under medical supervision for patients with severe mental disorders.
This significant shift has been groundbreaking for many mental health professionals and researchers. The administration of these substances will be stringently monitored; it’s not just about taking a pill and going home.
The treatment protocol typically involves three sessions spread over five to eight weeks. Each session lasts approximately eight hours, with the therapist remaining by the patient’s side throughout.
The Role of Canada in Psilocybin Research
Canada has established itself as a key player in psilocybin research, significantly expanding our understanding of this compound. Health Canada, in collaboration with various institutions, is leading the charge in investigating the therapeutic benefits of psilocybin for different mental health conditions.
Research institutions are no longer required to label these substances as illegal or rely on unauthorized dispensaries or mushroom shops. The government now permits certain institutions to grow psychedelic mushrooms for research.
The ease of access to substances once deemed harmful enables researchers to delve deeper into their potential benefits for many individuals.
A Cyclic Trends
The potential of mental health and substance abuse treatments, including alcoholism, was initially identified in the 1950s. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer pioneered this early research at Weyburn The Saskatchewan Mental Hospital. Under the leadership of then-premier Tommy Douglas, this hospital saw significant progress as the medical community was given considerable autonomy to investigate their theories.
Dr. Osmond and Dr. Hoffer ventured into research with LSD, mescaline, and peyote as potential alternatives to harsh treatments such as electroshock and lobotomy. The scope of their research expanded unexpectedly, leading them to advocate for medical professionals and auxiliary staff to experiment with these substances.
Research at Canadian Health Institutes
The Canadian Institutes of Health Research, through the Institute of Neurosciences, Mental Health and Addiction, is funding three clinical trials. These trials aim to evaluate the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Budget for the Project |
| A randomized controlled trial | Psychological distress at end-of-life in patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will pave the way for a deeper understanding of the benefits of controlled substances. It is made possible by the Canadian Drugs and Substances Strategy (CDSS), an initiative by the Government of Canada.
Further Psychedelic Research
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, also known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The treatment plan includes three eight-hour sessions with MDMA, spaced one month apart, and nine 90-minute sessions without the drug. This trial is considered historically important as it marks the first clinical evaluation of an illegal substance.
It’s been over forty years since a psychedelic substance was introduced.
An Overview of Psilocybin
Psilocybin is a psychedelic compound that naturally occurs in certain varieties of mushrooms. When ingested, it converts into psilocin. This psilocin activates the serotonin 5-HT2a receptors situated on cortical pyramidal cells in the brain, which serve as primary processing sites.
Authorities are examining the substance for its potential benefits in treating depression, anxiety, addiction, and distress related to end-of-life situations by promoting introspection and spiritual awakening.
Why is it Potentially Beneficial for Depression, PTSD, and Beyond?
This active compound interacts with various brain regions, suggesting its potential utility for diverse mental health conditions. Several patients in Canada and Australia have already undergone this therapy. The reported results are promising, with minor side effects like temporary anxiety or increased blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: The compound partially stimulates serotonin receptors, particularly the 5-HT2A subtype, which plays a vital role in emotional processing and mood balancing.
- Modulation of the Default Mode Network (DMN): This substance reduces the DMN’s activity, promoting introspection, reducing rigid thinking, and enhancing emotional flexibility.
- Stimulation of Prefrontal and Limbic Areas: The antidepressant effects of this substance are attributed to its impact on the prefrontal and limbic brain regions, including the amygdala. Depressed individuals often show reduced responsiveness to emotional cues. The compound increases the response to positive emotional stimuli in the right amygdala while decreasing or normalizing the response to negative or neutral emotional stimuli.
Effects on Psychology and Emotion:
- Promotion of Positive Emotional States: It fosters feelings of joy, interconnectedness, and emotional openness during and following the experience.
- Enhanced Emotional Processing: The psychedelic trip may allow individuals to confront and process deeply entrenched emotions, traumatic memories, or existential fears in a supportive setting.
- Spiritual and Existential Realizations: Studies from Johns Hopkins University and Imperial College London suggests that it can result in enduring beneficial changes, encompassing enhanced well-being, increased life satisfaction, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Outlets?
Interested in how the substance might affect your mental health? Explore magic mushroom stores to discover a product that suits your preferences.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, stimulates creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and improves the overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Enhances clarity, creativity, and concentration, with a powerful mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
International Acceptance of Psilocybin
Canada is not the sole country advocating for the use of magic mushrooms for mental health concerns. Countries such as Australia are also embracing these hallucinogens to address issues like depression and PTSD. They are procuring top-quality psychedelic capsules from trustworthy sources. With proper guidance, patients can significantly improve their life quality. Get Magic Mushrooms Canada, a magic mushroom supplier, offers a variety of products, including tablets and LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Psilocybin and MDMA both have therapeutic potential in enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Meanwhile, MDMA promotes empathy and proves beneficial in PTSD treatment. It demonstrates potential in improving emotional processing and
Despite being classified as a controlled substance, it has shown promising therapeutic results.
Is this treatment accessible to all Australians?
No. In Australia, individuals are required to undergo an assessment to ascertain their eligibility for using the substance. Such an evaluation takes into account aspects like pre-existing heart conditions, prior instances of psychosis, and others. This treatment is exclusively open to patients who have not found relief from conventional treatments for conditions such as depression, anxiety, or PTSD.
What implications does Canada’s export of mushrooms hold?
Canada is poised to take a leading role in the psychedelics market, mirroring its approach to cannabis. This could lead to an increased number of companies producing high-quality products. As a result, Canada could establish itself as a leader in the hallucinogen market, strengthen its economy, and make treatments more accessible to other countries. This would also discourage other nations from obtaining their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Articles You Might Find of Interest:
